This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RVT-103

Axovant Sciences, Inc.

Drug Names(s): RVT103

Description: RVT-103 is a combination of glycopyrrolate, a peripheral muscarinic receptor antagonist, and donepezil, a cholinesterase inhibitor, for the treatment of patients with dementia formulated with the company's Quaternary Ammonium Anti-Muscarinic – Cholinesterase Inhibitor (QAAM-CI) technology. Although details have not been released, QAAM-CI is designed to selectively inhibit acetylcholine outside the central nervous system to maximize aceylcholine levels in the brain.

Deal Structure: Axovant and Qaam
Axovant and Qaam have entered into an exclusive license agreement under which Axovant expects to develop and commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors.

Partners: Qaam Pharmaceuticals LLC


RVT-103 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug